Evaluation of Accuracy of CFD-based RuiXin-FFR by Comparing With Pressure-wire-based FFR

NCT ID: NCT04731285

Last Updated: 2021-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

316 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-13

Study Completion Date

2020-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Coronary Artery Disease (CAD) is the top killer nowadays. Pressure-wire-based Fractional Flow Reserve (FFR) is the gold standard for measuring ischemia in coronary arteries. CFD-based RuiXin-FFR, which is noninvasive, is developed recently. But its accuracy is not verified. This is a multi-center and prospective study to evaluate the sensitivity, specificity, and accuracy of CFD-based RuiXin-FFR compared with wire-based FFR.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The participants are entered with suspended CAD and angiography ischemia between 30%-90% from 6 hospitals in China. Pressure-wire-based FFR is conducted in the standard protocol by each hospital. FFR\>0.8 is chosen as the threshold to indicate non-ischemia. CFD-based RuiXin-FFR is performed by Raysight Medical (Shenzhen, China). CT images are acquired in a standard protocol by each hospital. Images with poor quality are excluded in this trial. Based on these images, RuiXin-FFR reconstructs the 3D model of coronary trees and obtains RuiXin-FFR values by conducting CFD simulations in a blinded fashion. RuiXin-FFR\>0.8 is chosen as the threshold to indicate non-ischemia as well. By comparing the clinical diagnosis outcome of pressure-wire-based FFR and CFD-based RuiXin-FFR, the sensitivity and specificity of the RuiXin-FFR are obtained, which is the primary end point of this trial. The secondary end point includes the measurement of accuracy, NPV, PPV and ROC of the RuiXin-FFR.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease Myocardial Ischemia Myocardial Fractional Flow Reserve

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pressure wire based FFR

Pressure wire based FFR was reference group

Pressure wire fractional flow reserve

Intervention Type DIAGNOSTIC_TEST

Pressure wire is inserted into coronary arteries. The ratio of the average distal pressure and average aorta pressure is FFR.

CT-FFR

CFD-based RuiXin-FFR was test group

CFD-based RuiXin-FFR

Intervention Type DIAGNOSTIC_TEST

CT-FFR was evaluated in a blinded fashion with a "Coarse-to-Fine Subpixel" algorithm for lumen contour

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pressure wire fractional flow reserve

Pressure wire is inserted into coronary arteries. The ratio of the average distal pressure and average aorta pressure is FFR.

Intervention Type DIAGNOSTIC_TEST

CFD-based RuiXin-FFR

CT-FFR was evaluated in a blinded fashion with a "Coarse-to-Fine Subpixel" algorithm for lumen contour

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* able to understand the purpose of the study and sign the informed consent
* with diagnosed or confirmed coronary artery disease according to the comprehensive clinical assessment
* with CTA image indicating that the diameter of the reference vessel in the stenosis segment was ≥2mm
* with CTA image indicating that the stenosis degree of coronary artery lumen diameter ≥30% and ≤90%

Exclusion Criteria

* prior coronary artery bypass bypass (CABG) surgery, coronary interventional therapy (PCI), artificial heart valve implantation, cardiac pacemaker or implantable defibrillator implantation
* persistent or active symptoms of clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure status (systolic pressure less than 90 mmHg), severe congestive heart failure (NYHA grade III or IV), or acute pulmonary edema
* acute myocardial infarction occurred within 7 days before inclusion
* complex congenital heart disease, sick sinus syndrome, long QT syndrome, severe arrhythmia, tachycardia, severe asthma, severe or very severe chronic obstructive pulmonary disease (COPD) and chronic renal damage (serum creatinine value \> 1.5 mg/dl or creatinine clearance \< 45 ml/Kg\*1.73 m2)
* there are contraindications for the use of adenosine disodium triphosphate
* allergic to iodized contrast media
* pregnancy or pregnancy status unknown
* life expectancy less than 2 months
* there are any factors that other researchers consider not suitable for inclusion or completion of this study
* obvious mismatch of coronary artery CTA images
* CTA image showing calcification occupies the cross-sectional area of the lumen \> 80%
* CT value standard deviation of aortic root image \>30HU
* coronary artery occlusion.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Anzhen Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shao-Ping Nie

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zhanquan Li, MD

Role: PRINCIPAL_INVESTIGATOR

Liaoning Provincial People's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shaoping Nie

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

References

Explore related publications, articles, or registry entries linked to this study.

Zeng Y, Wang X, Tang Z, Li T, Jiang X, Ji F, Zhou Y, Ge J, Li Z, Zhao Y, Ma C, Mintz GS, Nie S. Diagnostic accuracy of CT-FFR with a new coarse-to-fine subpixel algorithm in detecting lesion-specific ischemia: a prospective multicenter study. Rev Esp Cardiol (Engl Ed). 2024 Feb;77(2):129-137. doi: 10.1016/j.rec.2023.05.008. Epub 2023 Jul 13. English, Spanish.

Reference Type DERIVED
PMID: 37453536 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

201901RX

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Flash FFR Ⅱ Study
NCT04575207 RECRUITING NA